Atrophy of the Substantia innominata on Magnetic Resonance Imaging Predicts Response to Donepezil Treatment in Alzheimer’s Disease Patients

To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer’s disease (AD), we studied correlations between the thickness of the substantia innominata and clinical efficacy. Eighty-two patients were divided into responders, including transiently and continuously responding groups, and nonresponders, based on the changes in the Mini-Mental State Examination (MMSE) score from baseline at 3 months and at 12 months. Atrophy of the substantia innominata was more pronounced in transiently and continuously responding groups than nonresponders, but no significant change in the thickness between transiently and continuously responding groups was found. The MMSE score changes from baseline at 3 months and at 12 months significantly inversely correlated with the thickness of the substantia innominata. Logistic regression analysis revealed that the overall discrimination rate with the thickness of the substantia innominata was 70% between responders and nonresponders. We conclude that atrophy of the substantia innominata on MRI helps to predict response to donepezil treatment in patients with AD.

[1]  B. Everitt,et al.  AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[2]  K. Rockwood,et al.  Donepezil for Treatment of Dementia With Lewy Bodies: A Case Series of Nine Patients , 1998, International Psychogeriatrics.

[3]  J. Muir,et al.  Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron , 1995, Psychopharmacology.

[4]  B. Sahakian,et al.  Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB , 2005, Psychopharmacology.

[5]  M. Memo,et al.  Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease? , 1996, Trends in pharmacological sciences.

[6]  N. Herrmann,et al.  Donepezil for behavioural disorders associated with Lewy bodies: a case series , 2000, International journal of geriatric psychiatry.

[7]  R. Nieuwenhuys,et al.  Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease , 1990, Neurobiology of Aging.

[8]  L. Thal,et al.  Cholinergic dysfunction in diseases with Lewy bodies , 2000, Neurology.

[9]  K. Davis,et al.  Cholinergic markers in elderly patients with early signs of Alzheimer disease. , 1999, JAMA.

[10]  L. Sands,et al.  Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors. , 1999, Alzheimer disease and associated disorders.

[11]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[12]  ML Voytko,et al.  Basal forebrain lesions in monkeys disrupt attention but not learning and memory [published erratum appears in J Neurosci 1995 Mar;15(3): following table of contents] , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  J. Rusted,et al.  Cholinergic control of cognitive resources. , 1993, Neuropsychobiology.

[14]  R. Levy,et al.  The Lewy-Body Variant of Alzheimer's Disease , 1993, British Journal of Psychiatry.

[15]  H. Hanyu,et al.  MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. , 2002, AJNR. American journal of neuroradiology.

[16]  E. Giacobini,et al.  Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease. , 2000, Alzheimer disease and associated disorders.

[17]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[18]  D. Galasko,et al.  Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies , 1993, Neurology.

[19]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[20]  G. Blessed,et al.  NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA , 1977, The Lancet.

[21]  Mrinalini Honavar,et al.  Lewy bodies and response to tacrine in Alzheimer's disease , 1994, The Lancet.

[22]  H. Tohgi,et al.  MR anatomy of the substantia innominata and findings in Alzheimer disease: a preliminary report. , 1995, AJNR. American journal of neuroradiology.

[23]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[24]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[25]  K. Davis,et al.  Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. , 1994, Neuroreport.

[26]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[27]  D M Bowen,et al.  Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. , 1976, Brain : a journal of neurology.

[28]  B. Winblad,et al.  EEG regional changes during long‐term treatment with tetrahydroaminoacridine (THA) in Alzheimer's disease , 1993, Acta neurologica Scandinavica. Supplementum.

[29]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[30]  Hirofumi Sakurai,et al.  Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease , 2002, Neuroscience Letters.